- Overview of our evolving understanding of the genetics/pathogenesis of CLL
- Case challenges in patients with treatment-naive CLL: treatment options for optimal outcomes
- Case challenges in patients with relapsed/refractory CLL: current and novel treatment strategies
- Intraclass and interclass comparison of current and emerging CLL therapies
Date / Time
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Ian W. Flinn, MD, PhD
Director, Lymphoma Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Jeremy S. Abramson, MD, MMSc
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York
Jonathon B. Cohen, MD
Hematology & Medical Oncology
Emory University Winship Cancer Institute
Co-Director, Lymphoma Program
Hematology & Medical Oncology
Winship Cancer Institute
Brian T. Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
John S. Renshaw, MD
San Antonio, Texas
This series of 1-hour, expert-led live workshops present the latest best practices and clinically relevant investigational data for the optimal management of patients with chronic lymphocytic leukemia (CLL).
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current and emerging best practices in the treatment of chronic lymphocytic leukemia.
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with chronic lymphocytic leukemia.
Upon completion of this activity, participants should be able to:
- Plan individualized therapy to patients with newly diagnosed and relapsed/refractory CLL, based on available data, expert recommendations, and patient preferences to optimize outcomes and quality of life
- Compare and contrast the known efficacy and toxicity profiles of available and investigational agents with the same target
- Manage adverse events associated with the most common treatments for CLL to ensure treatment compliance as well as improved clinical outcomes and quality of life
- Evaluate promising approved and investigational agents and combination regimens in CLL, including efficacy, unique toxicities, dosing, and other practical management considerations
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-21-140-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.